sábado, 7 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree

View original at finance.yahoo.com
5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree If any investor has stood the test of time, it’s Warren Buffett, and with good reason…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The portfolio will remain concentrated in a small group of companies

    60% confidence
  • Greg Abel will use all of his $25 million per year salary to buy shares in Berkshire Hathaway

    60% confidence
  • The course forward would remain the same, and he would directly oversee the equity portfolio, with Ted Weschler continuing to manage about 6% of it. The portfolio will remain concentrated in a small group of companies.

    60% confidence
  • Greg Abel will use all of his $25 million per year salary to buy shares in Berkshire Hathaway

    60% confidence
  • The course forward would remain the same, and he would directly oversee the equity portfolio, with Ted Weschler continuing to manage about 6% of it

    60% confidence
  • Warren Buffett's favorite holding period for an S&P 500 stock is forever

    60% confidence
  • Warren Buffett vows to come to the office every day and continue to have a voice in day-to-day operations

    60% confidence
  • His favorite holding for an S&P 500 stock is forever

    60% confidence
  • Warren Buffett will remain board chair and come to the office every day, continuing to have a voice in day-to-day operations

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree — Source | Via News | es.VIA.NEWS